Ferdinand Keith C, Arora Neha
John W. Deming Department of Medicine, Section of Cardiology, Tulane University School of Medicine, New Orleans, LA, USA.
Am Heart J Plus. 2022 Jun 28;21:100159. doi: 10.1016/j.ahjo.2022.100159. eCollection 2022 Sep.
The use of SGLT2 inhibitors, beyond present guideline-directed medical therapy for patients with type 2 diabetes, chronic kidney disease, high atherosclerotic cardiovascular risk and heart failure, may in the future become a significant addition to the treatment of patients with acute myocardial infarction. Ongoing studies, including the PREDOMINANCE trial, may prove beneficial with this class of agents, already demonstrated to improve outcomes in a wide range of patients, with and without type 2 diabetes. Cardiovascular specialists would benefit from increasing their familiarity with this proven therapeutic class in patients with cardiometabolic and cardiovascular disease and increase their utilization in appropriate patients.
对于2型糖尿病、慢性肾脏病、高动脉粥样硬化心血管风险及心力衰竭患者，除了目前指南指导的药物治疗外，使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂未来可能会成为急性心肌梗死患者治疗的一项重要补充。包括PREDOMINANCE试验在内的正在进行的研究，可能会证明这类药物有益，这类药物已被证明可改善各类患者的预后，无论患者有无2型糖尿病。心血管专科医生若能更加熟悉这类已被证实对心脏代谢和心血管疾病患者有效的治疗药物，并在合适的患者中增加其使用，将会从中受益。
